Mostrar el registro sencillo del ítem
Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age
dc.contributor.author | Plaza Díaz, Julio | |
dc.contributor.author | Ruiz Ojeda, Francisco Javier | |
dc.contributor.author | Gil Hernández, Ángel | |
dc.date.accessioned | 2023-06-28T11:26:40Z | |
dc.date.available | 2023-06-28T11:26:40Z | |
dc.date.issued | 2023-04-17 | |
dc.identifier.citation | Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; Morales, J.; Martín-Masot, R.; Climent, E.; Silva, Á.; Martinez-Blanch, J.F.; Enrique, M.; Tortajada, M.; Ramon, D.; et al. Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age. Int. J. Mol. Sci. 2023, 24, 7392. [https:// doi.org/10.3390/ijms24087392] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/82928 | |
dc.description.abstract | The World Health Organization recommends exclusive breastfeeding on demand until at least the sixth month of life. Breast milk or infant formula is the infant’s primary food source until the age of one year, followed by the gradual introduction of other foods. During weaning, the intestinal microbiota evolves to a profile close to that of the adult, and its disruption can result in an increased incidence of acute infectious diseases. We aimed to determine whether a novel starting formula (INN) provides gut microbiota compositions more similar to those of breastfed (BF) infants from 6 to 12 months of age compared to a standard formula (STD). This study included 210 infants (70 per group) who completed the intervention until they reached the age of 12 months. In the intervention period, infants were divided into three groups. Group 1 received an INN formula with a lower protein content, a casein to whey protein ratio of approximately 70/30, twice as much docosahexaenoic acid as the STD formula, a thermally inactivated postbiotic (Bifidobacterium animalis subsp. lactis, BPL1TM HT), and twice as much arachidonic acid as the STD formula contained. The second group received the STD formula, while the third group was exclusively BF for exploratory purposes. In the course of the study, visits were conducted at 6 months and 12 months of age. Compared to the BF and STD groups, the Bacillota phylum levels in the INN group were significantly reduced after 6 months. At the end of 6 months, the alpha diversity indices of the BF and INN groups differed significantly from those of the STD group. At 12 months, the Verrucomicrobiota phylum levels in the STD group were significantly lower than those in the BF and INN groups. Based on the comparison between 6 and 12 months, the Bacteroidota phylum levels in the BF group were significantly higher than those in the INN and STD groups. When comparing the INN group with the BF and STD groups, Clostridium sensu stricto 1 was significantly higher in the INN group. The STD group had higher levels of calprotectin than the INN and BF groups at 6 months. The immunoglobulin A levels in the STD group were significantly lower than those in the INN and BF groups after 6 months. Both formulas had significantly higher levels of propionic acid than the BF group at 6 months. At 6 months, the STD group showed a higher quantification of all metabolic pathways than the BF group. The INN formula group exhibited similar behavior to the BF group, except for the superpathway of phospholipid biosynthesis (E. coli). We hypothesize that the novel INN formula may promote an intestinal microbiota that is more similar to the microbiota of an infant who consumes only human milk before the weaning period. | es_ES |
dc.description.sponsorship | Alter Farmacia S A as part of the INNOVA2020 project | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | α-lactalbumin | es_ES |
dc.subject | Arachidonic acid | es_ES |
dc.subject | Bifidobacterium animalis subsp. lactis | es_ES |
dc.subject | BPL1TM | es_ES |
dc.subject | Docosahexaenoic acid | es_ES |
dc.subject | Infant formula | es_ES |
dc.subject | Body composition | es_ES |
dc.subject | Postbiotics | es_ES |
dc.title | Innova 2020: A Follow-Up Study of the Fecal Microbiota of Infants Using a Novel Infant Formula between 6 Months and 12 Months of Age | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.3390/ijms24087392 | |
dc.type.hasVersion | VoR | es_ES |